2 Biotech Stocks Worth Buying Before Their Potential Buyouts

Dealmaking is back with a vengeance in the pharmaceutical sector this year. According to a report by PwC, there were more than $65 billion in pharma and life sciences mergers & acquisitions in the first quarter, the best quarter for the sector since 2020. The report said the quarter had 16 M&A deals of at least $1 billion each.

In the second quarter, the pace hasn't slowed, with Sun Pharmaceuticals announcing in April that it would acquire Organon for $11.75 billion and AbbVie reporting in June that it would acquire Apogee Therapeutics for $10.9 billion. Many deals focus on biotech stocks that use gene editing and other unique technologies. When a larger pharmaceutical company acquires a biotech stock, it is often at a premium to the biotech's stock price, rewarding its investors.

Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »

If you're wondering which biotech stocks might be the next takeover targets, consider Legend Biotech (NASDAQ: LEGN) and BioNTech (NA

Fuente original: Yahoo Finance (https://finance.yahoo.com/healthcare/articles/2-biotech-stocks-worth-buying-180500976.html)